Sepsis diagnostics market seen reaching $1.69 billion by 2035

Market Research Future says the global sepsis diagnostics market will grow from $0.91 billion in 2026 to $1.69 billion by 2035, driven by rising sepsis cases, faster molecular testing and reimbursement pressure. The report points to North America as the largest market and Asia-Pacific as the fastest-growing region.

Why it matters: - Sepsis remains a major global cause of death, keeping demand high for faster diagnostics that can guide treatment decisions in hours, not days. - The market outlook suggests hospitals will keep shifting spending from legacy blood culture systems to molecular and biomarker-based tests. - Reimbursement and stewardship rules are turning sepsis testing into a priority for health systems rather than a discretionary lab expense.

What happened: - Market Research Future projects the global sepsis diagnostics market will reach $1.69 billion by 2035, up from $0.91 billion in 2026. - The report places the market at $0.85 billion in 2025 and forecasts a 7.1% compound annual growth rate from 2026 to 2035. - The release was issued June 23, 2026. - A free sample is available here. - The full report is available here.

The details: - Rising sepsis incidence is expanding the patient pool for rapid pathogen identification. - The report cites Global Burden of Disease data showing 48.9 million sepsis cases and 11 million sepsis-related deaths in 2017. - WHO surveillance data through 2023 indicates sepsis incidence in low- and middle-income countries has risen an estimated 12% since 2017. - Molecular diagnostics are replacing legacy blood cultures that can take 24 to 72 hours. - Multiplex PCR and biomarker-driven platforms can return actionable results in under three hours. - The European Commission’s Horizon Europe program has committed EUR 240 million from 2021 to 2027 for antimicrobial resistance diagnostics, including next-generation sepsis panels. - The U.S. FDA has used Breakthrough Device Designation to speed clearances for multiplex PCR sepsis panels, cutting approval timelines from 18 months to as few as 8 months. - CMS SEP-1 and the Hospital Value-Based Purchasing Program tie reimbursement to early sepsis protocol compliance. - European data from the ECDC show rapid pathogen identification can reduce inappropriate antibiotic use by about 30% to 40% per patient.

Between the lines: - The market’s growth is being driven by policy, reimbursement and clinical workflow changes, not just by test innovation. - Hospital buyers appear to be favoring platforms that support both rapid diagnosis and antimicrobial stewardship goals. - The report also suggests emerging markets are widening the revenue base as more hospitals gain access to sepsis testing.

What's next: - Market Research Future expects molecular diagnostics and AI-integrated clinical decision support to shape sepsis management by 2030. - The report forecasts that about 40% of newly diagnosed sepsis cases in academic medical centers will get multiplex PCR testing followed by matched antimicrobial therapy by 2030. - Machine-learning tools that combine vital signs, lab values and electronic health record data may identify sepsis 4 to 6 hours before clinical recognition. - Growth will likely continue in Asia-Pacific, where the report says the region will post an 8.9% CAGR from 2026 to 2035.

The bottom line: - Sepsis diagnostics is moving from a niche lab category to a core hospital workflow, with faster molecular testing and reimbursement incentives doing most of the work.